First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

NCT05054348 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

BIOLOGICAL: IO-108
BIOLOGICAL: IO-108 + pembrolizumab combination therapy
BIOLOGICAL: IO-108 + cemiplimab combination therapy

Sponsor

Immune-Onc Therapeutics

Collaborators

[object Object]